No Borders, Inc. (OTCMKTS: NBDR) started moving last week after the Company jumped on the covid bandwagon announcing the launch of its MediDent Supplies Covid-19 Home Specimen Collection Kit to support the #StayHomeSaveLives efforts across the country. This kit is designed with the idea to be processable by any one of the over 2,000 Covid-19 approved labs in the country by containing specimen collection equipment for Nasal, Throat and Saliva samples. With direct to home delivery, people who would otherwise have to go to a doctors office while ill can prepare their specimens for testing without ever leaving their home.
NBDR popped off its $0.01 base last week on significant volume to highs near $0.06 after the big news but dropped right back to where it started. NBDR is on the move again after the Company said they executed an agreement with its existing suppliers in Hong Kong to bring its 15 minute “At Home” Serological COVID-19 test to the USA.
No Borders, Inc. (OTCMKTS: NBDR) bills itself as a multifaceted corporation specializing in the acquisition, creation and scaling of commercial and consumer products by utilizing cutting-edge technologies to reduce costs while increasing revenues and shareholder value through technological superiority and Intellectual Property ownership across its portfolio of assets. The Companys portfolio of brands includes: No Borders Naturals Inc., a purveyor of health and wellness products for active consumers and their pets. No Borders Labs Inc., which provides leading-edge tech tools to NBDR internal companies while also offering consulting, architecture and software development services to external businesses looking to update their technology infrastructure for greater efficiency, security and transparency. CBDLabChain is a powerful, Patent Pending tool to demonstrate in an unbiased and unchangeable way a clear sense of security to consumers of CBD products by recording Certificate Of Authority (COA) on a blockchain technology platform. No Borders Dental Resources Inc., a provider of equipment and supplies to medical and dental professionals across the U.S. through the trade name MediDent Supplies.
To Find out the inside Scoop on NBDR Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On March 23 NBDR reported it executed an agreement with its existing suppliers in Hong Kong to bring its 15 minute “At Home” Serological COVID-19 test to the USA. The brand new “MediDent Supplies 15 Minute Rapid Result Covid-19 Test” is being manufactured by a MediDent Supplies partner with existing US FDA registrations for both the manufacturer and the serological test kit itself. MediDent Supplies is actively engaged with the FDA to obtain an Emergency Use Authorization for its COVID-19 blood test and the Company believes due to a recent update to the FDA COVID-19 testing guidelines which now include serological testing as an acceptable means of testing, that it will receive expedited approval for these tests very quickly.
MediDent Supplies has already purchased thousands of units of this test and has expedited Air Freight delivery of these tests to the USA in order to be fully ready to distribute them nationwide the moment the Company’s EUA is processed by the FDA. No Borders is actively engaged with the FDA, FEMA, Congressman Paul Gosar’s and Congressman Kevin McCarthy’s offices and is proud to have direct support from these and many other government members in its efforts to move quickly, deploy nationally and help Americans combat the COVID-19 epidemic.
Joseph Snyder, CEO of MediDent Supplies stated: “Our entire team is committed to deploying every ounce of effort we can to help America through this trying time. Millions of people around the world have used these serological tests to identify COVID-19 antibodies in the blood and these tests will have a dramatic impact on America’s ability to scale national real time testing efforts with a proven, effective blood test. Working quickly with our partners in Hong Kong and government officials here in the USA we have already purchased and expedited shipment of thousands of units of these tests. With the existing FDA registrations for our manufacturing partner and the test as a medical device in hand I believe that MediDent Supplies will be able to receive an expedited EUA from the FDA within weeks if not days. In order to mitigate lag time in bringing these critically needed ‘At Home 15 Minute COVID-19 Blood Tests’ to Americans all around the USA, the Board of Directors has approved the purchase and expedited shipment of our first batch of tests and they are being shipped immediately. I am incredibly proud of our No Borders and MediDent Supplies teams; it is simply breathtaking to see how much people care and give. Please stay home, cover your cough and WASH YOUR HANDS.”
We will cont. to take massive, immediate action to deploy every resource we have to combat #coronavirus around the 🌎- today we have NO LAB blood tests already paid4 & headed to 🇺🇸while we work to receive FDA EUA. Our tests are registered med devices with FDA will need EUA. $NBDR https://t.co/RtGvXg2bdL
— No Borders, Inc. $NBDR (@NoBordersNBDR) March 23, 2020
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $6 million market valuation NBDR is non reporting with little cash, very little debt and small but growing revenues reporting $280k in sales for the 9 months ended September 30, 2019. NBDR is making a fast move up after announcing they executed an agreement with existing suppliers in Hong Kong to bring its 15 minute “At Home” Serological COVID-19 test to the USA. This comes after the Company initially jumped on the covid bandwagon last week reporting the launch of its MediDent Supplies Covid-19 Home Specimen Collection Kit to support the #StayHomeSaveLives efforts across the country. We will be updating on NBDR when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with NBDR.
Sign Up now for our 100% FREE Penny Stock Newsletter
Disclosure: we hold no position in NBDR either long or short and we have not been compensated for this article.